JP2019530671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530671A5 JP2019530671A5 JP2019513333A JP2019513333A JP2019530671A5 JP 2019530671 A5 JP2019530671 A5 JP 2019530671A5 JP 2019513333 A JP2019513333 A JP 2019513333A JP 2019513333 A JP2019513333 A JP 2019513333A JP 2019530671 A5 JP2019530671 A5 JP 2019530671A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- dash
- lower alkyl
- antagonist
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 239000005557 antagonist Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 36
- 125000003342 alkenyl group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 15
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 claims description 14
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 claims description 13
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 10
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 8
- 229960002986 dinoprostone Drugs 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 4
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 229940111134 coxibs Drugs 0.000 claims description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 210000005008 immunosuppressive cell Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical group CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 3
- 102000015439 Phospholipases Human genes 0.000 claims description 3
- 108010064785 Phospholipases Proteins 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 125000004437 phosphorous atom Chemical group 0.000 claims description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 229940124639 Selective inhibitor Drugs 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 238000011467 adoptive cell therapy Methods 0.000 claims description 2
- 125000000539 amino acid group Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 244000309459 oncolytic virus Species 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000006010 pyroptosis Effects 0.000 claims 1
- WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 0 CC*C=CC(C)(CC)N* Chemical compound CC*C=CC(C)(CC)N* 0.000 description 4
- -1 CEACAM Proteins 0.000 description 3
- 102100024263 CD160 antigen Human genes 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022079413A JP7617640B2 (ja) | 2016-09-07 | 2022-05-13 | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384403P | 2016-09-07 | 2016-09-07 | |
| US201662384407P | 2016-09-07 | 2016-09-07 | |
| US62/384,403 | 2016-09-07 | ||
| US62/384,407 | 2016-09-07 | ||
| US201762482750P | 2017-04-07 | 2017-04-07 | |
| US62/482,750 | 2017-04-07 | ||
| PCT/US2017/050474 WO2018049027A1 (en) | 2016-09-07 | 2017-09-07 | Combination therapies using immuno-dash inhibitors and pge2 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079413A Division JP7617640B2 (ja) | 2016-09-07 | 2022-05-13 | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530671A JP2019530671A (ja) | 2019-10-24 |
| JP2019530671A5 true JP2019530671A5 (cg-RX-API-DMAC7.html) | 2020-10-15 |
| JP7096598B2 JP7096598B2 (ja) | 2022-07-06 |
Family
ID=61561557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513333A Active JP7096598B2 (ja) | 2016-09-07 | 2017-09-07 | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
| JP2022079413A Active JP7617640B2 (ja) | 2016-09-07 | 2022-05-13 | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079413A Active JP7617640B2 (ja) | 2016-09-07 | 2022-05-13 | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US11583516B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3509604A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7096598B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102557900B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109906082A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3036202A1 (cg-RX-API-DMAC7.html) |
| WO (4) | WO2018049015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42459A (fr) | 2015-07-16 | 2018-05-23 | Bioxcel Therapeutics Inc | Nouvelle approche pour le traitement du cancer par immunomodulation |
| CN109906082A (zh) | 2016-09-07 | 2019-06-18 | 塔夫茨大学信托人 | 使用免疫dash抑制剂和pge2拮抗剂的组合治疗 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11559537B2 (en) * | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
| WO2019017420A1 (ja) * | 2017-07-20 | 2019-01-24 | 国立大学法人北海道大学 | Ｐｄ－１／ｐｄ－ｌ１を標的とする阻害薬とｃｏｘ－２阻害薬との併用 |
| KR20250056192A (ko) | 2017-08-07 | 2025-04-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| CA3101640A1 (en) * | 2018-06-04 | 2019-12-12 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
| WO2020123477A1 (en) * | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist |
| CN109706243A (zh) * | 2018-12-18 | 2019-05-03 | 南通大学附属医院 | Dpp9基因在制备治疗胃癌药物及其诊断试剂盒中的应用 |
| EP3946434A1 (en) | 2019-04-02 | 2022-02-09 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
| WO2021011592A1 (en) * | 2019-07-16 | 2021-01-21 | Virginia Commonwealth University | Compounds as nlrp3 inflammasome inhibitors and compositions and uses thereof |
| WO2021036793A1 (en) * | 2019-08-23 | 2021-03-04 | National Institute Of Biological Sciences, Beijing | Pyroptosis-induced immunotherapy |
| CN110951672B (zh) * | 2019-12-16 | 2021-09-24 | 武汉大学 | 一种小鼠子宫内膜上皮细胞及其3d分化培养物模型的构建方法 |
| AU2021211732A1 (en) * | 2020-01-23 | 2022-08-25 | Myoforte Therapeutics, Inc. | PGDH inhibitors and methods of making and using |
| US20240148736A1 (en) * | 2020-12-14 | 2024-05-09 | Saitama Medical University | Combination drug for treating renal cancer and potentiator for therapeutic effects of tyrosine kinase inhibitor |
| US20240158352A1 (en) * | 2021-02-26 | 2024-05-16 | Can-Therapy Inc. | Novel adamantyl derivative or pharmaceutically acceptable salt thereof, and use thereof |
| CN113337569A (zh) * | 2021-05-26 | 2021-09-03 | 深圳市人民医院 | 一种基于诱导细胞炎性死亡的抗肿瘤药物筛选方法 |
| KR20240135691A (ko) * | 2021-12-09 | 2024-09-11 | 매터리어 테라퓨틱스 인크. | 관문 억제제와 병용하여 케토티펜을 사용하는 암 치료 방법 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2756113A1 (de) | 1977-12-16 | 1979-06-21 | Thomae Gmbh Dr K | Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4885367A (en) | 1987-11-19 | 1989-12-05 | Taisho Pharmaceutical Co., Ltd. | Sulfonanilide compounds |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| CA2152792C (en) | 1993-01-15 | 2000-02-15 | Stephen R. Bertenshaw | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
| CA2113787A1 (en) | 1993-01-29 | 1994-07-30 | Nobuyuki Hamanaka | Carbocyclic sulfonamides |
| US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| DE69422306D1 (de) | 1993-11-30 | 2000-01-27 | Searle & Co | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| EP1125932A3 (en) | 1994-07-27 | 2001-08-29 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| US5739166A (en) | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
| JP2636819B2 (ja) | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
| JP3181190B2 (ja) | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
| US5596008A (en) | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| DE10399017I1 (de) | 1995-02-13 | 2012-05-16 | Searle & Co | Substituierte isoxazole zur Behandlung von entzuendung |
| US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| CA2223154A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| WO1997003668A1 (en) | 1995-07-21 | 1997-02-06 | Constantia Gruppe | Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles |
| JPH11510485A (ja) | 1995-07-21 | 1999-09-14 | ニィコメド・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 酵素のシクロオキシゲナーゼｉｉの阻害剤としてのベンゼンスルホンアミドの誘導体 |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JPH0977664A (ja) | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤 |
| US6020343A (en) | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| US5981576A (en) | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| US6057319A (en) | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| US6180651B1 (en) | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
| GEP20032998B (en) | 1996-04-12 | 2003-06-25 | Searle & Co | Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors |
| SE9601939L (sv) | 1996-05-22 | 1997-04-14 | Bo Granbom | Bromsanordning vid manöverdon för linjär rörelse |
| US5883267A (en) | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
| GB9615867D0 (en) | 1996-07-03 | 1996-09-11 | Merck & Co Inc | Process of preparing phenyl heterocycles useful as cox-2 inhibitors |
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| CA2260016C (en) | 1996-07-18 | 2004-03-09 | Merck Frosst Canada Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
| EP0863134A1 (en) | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| EP1006114B1 (en) | 1997-04-11 | 2003-01-22 | Grelan Pharmaceutical Co., Ltd. | Pyrazole derivatives and cox inhibitors containing them |
| US6130334A (en) | 1998-04-15 | 2000-10-10 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
| US6127545A (en) | 1997-04-18 | 2000-10-03 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
| US6077850A (en) | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| WO1999003837A1 (en) | 1997-06-30 | 1999-01-28 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| JP2002511887A (ja) | 1997-08-22 | 2002-04-16 | アボツト・ラボラトリーズ | プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害薬 |
| WO1999010331A1 (en) | 1997-08-22 | 1999-03-04 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| EP1032575B1 (en) | 1997-09-05 | 2003-07-23 | Glaxo Group Limited | 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| US5925769A (en) | 1997-09-09 | 1999-07-20 | Ortho Pharmaceutical, Corp. | Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents |
| US6046217A (en) | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
| US6140515A (en) | 1997-09-24 | 2000-10-31 | Merck & Co., Inc. | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2 |
| US6040450A (en) | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
| US6080876A (en) | 1997-10-29 | 2000-06-27 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as COX-2 inhibitors |
| US6133292A (en) | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| WO1999038501A2 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| US20010031275A1 (en) | 1998-02-09 | 2001-10-18 | Forse R Armour | Sesamol inhibitor of delta-5-desaturase activity and uses therefor |
| JP3256513B2 (ja) | 1998-02-11 | 2002-02-12 | ファイザー製薬株式会社 | ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤 |
| US5994379A (en) | 1998-02-13 | 1999-11-30 | Merck Frosst Canada, Inc. | Bisaryl COX-2 inhibiting compounds, compositions and methods of use |
| AU4428899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of cyclooxygenase-2 |
| KR100295206B1 (ko) | 1998-08-22 | 2001-07-12 | 서경배 | 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물 |
| TW587079B (en) | 1998-09-25 | 2004-05-11 | Almirall Prodesfarma Ag | 2-phenylpyran-4-one derivatives |
| KR100666838B1 (ko) | 1998-10-27 | 2007-01-11 | 아보트 러보러터리즈 | 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제 및 이를 포함하는 약제학적 조성물 |
| US6077869A (en) | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
| ES2234324T3 (es) | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
| EP1135141A4 (en) | 1998-11-12 | 2003-03-05 | Analytica Ltd | PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1157025B1 (en) | 1999-02-27 | 2004-03-10 | Glaxo Group Limited | Pyrazolopyridines |
| GB9906714D0 (en) * | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| EA004432B1 (ru) | 1999-04-14 | 2004-04-29 | Пасифик Корпорейшн | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 |
| EP1191931B1 (en) | 1999-06-16 | 2007-05-09 | Temple University of the Commonwealth System of Higher Education | 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| MXPA00006605A (es) | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
| US6077868A (en) | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
| US6472416B1 (en) | 1999-08-27 | 2002-10-29 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors |
| US6306890B1 (en) | 1999-08-30 | 2001-10-23 | Vanderbilt University | Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6083969A (en) | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6465509B2 (en) | 2000-06-30 | 2002-10-15 | Merck Frosst Canada & Co. | Pyrones as inhibitors of cyclooxygenase-2 |
| AR030630A1 (es) | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| KR100809489B1 (ko) | 2001-10-10 | 2008-03-03 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난4'-메탄설포닐-비페닐 유도체 |
| KR100810468B1 (ko) | 2001-10-10 | 2008-03-07 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체 |
| WO2003037351A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors |
| US6555563B1 (en) | 2001-11-16 | 2003-04-29 | Medinox, Inc. | Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation |
| CA2837936A1 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| US20030165588A1 (en) | 2002-03-01 | 2003-09-04 | Unigen Pharmaceuticals, Inc. | Identification of free-B-ring flavonoids as potent COX-2 inhibitors |
| MXPA05003091A (es) | 2002-09-19 | 2005-05-27 | Abbott Lab | Composiciones farmaceuticas como inhibidores de peptidasa de dipeptidilo-iv de (dpp-iv). |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| US8512717B2 (en) | 2003-08-07 | 2013-08-20 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| AU2005216970B2 (en) * | 2004-02-23 | 2011-07-07 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism |
| JP4568361B2 (ja) | 2005-04-22 | 2010-10-27 | アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2633803A1 (en) | 2005-12-19 | 2007-09-07 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
| WO2007117419A2 (en) | 2006-03-31 | 2007-10-18 | Dara Biosciences, Inc. | Methods and compositions relating to post-prolyl cleaving enzyme inhibitors |
| WO2007123686A2 (en) | 2006-03-31 | 2007-11-01 | Point Therapeutics, Inc. | Dpp inhibitors and uses thereof |
| WO2007127204A2 (en) | 2006-04-24 | 2007-11-08 | Dara Biosciences, Inc. | Methods and compositions relating to immunostimulation |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CA2715166C (en) | 2008-02-11 | 2017-05-16 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP2012522015A (ja) * | 2009-03-27 | 2012-09-20 | ブリストル−マイヤーズ スクイブ カンパニー | Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US8518945B2 (en) * | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| CA2856379A1 (en) * | 2011-11-22 | 2013-05-30 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| US20150202218A1 (en) * | 2012-08-02 | 2015-07-23 | Trustees Of Tufts College | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections |
| CN104003922A (zh) | 2013-02-27 | 2014-08-27 | 中国药科大学 | 取代吡咯烷类衍生物及其制备方法和在医药上的用途 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA42459A (fr) * | 2015-07-16 | 2018-05-23 | Bioxcel Therapeutics Inc | Nouvelle approche pour le traitement du cancer par immunomodulation |
| CN109906082A (zh) | 2016-09-07 | 2019-06-18 | 塔夫茨大学信托人 | 使用免疫dash抑制剂和pge2拮抗剂的组合治疗 |
| US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
| WO2018187698A2 (en) | 2017-04-07 | 2018-10-11 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists |
| CA3101640A1 (en) | 2018-06-04 | 2019-12-12 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
-
2017
- 2017-09-07 CN CN201780068517.6A patent/CN109906082A/zh active Pending
- 2017-09-07 US US16/331,181 patent/US11583516B2/en active Active
- 2017-09-07 WO PCT/US2017/050457 patent/WO2018049015A1/en not_active Ceased
- 2017-09-07 KR KR1020197009726A patent/KR102557900B1/ko active Active
- 2017-09-07 JP JP2019513333A patent/JP7096598B2/ja active Active
- 2017-09-07 EP EP17849528.9A patent/EP3509604A4/en active Pending
- 2017-09-07 WO PCT/US2017/050445 patent/WO2018049008A1/en not_active Ceased
- 2017-09-07 WO PCT/US2017/050455 patent/WO2018049014A1/en not_active Ceased
- 2017-09-07 US US16/331,346 patent/US11096924B2/en active Active
- 2017-09-07 CA CA3036202A patent/CA3036202A1/en active Pending
- 2017-09-07 WO PCT/US2017/050474 patent/WO2018049027A1/en not_active Ceased
-
2021
- 2021-07-06 US US17/368,161 patent/US11957657B2/en active Active
-
2022
- 2022-05-13 JP JP2022079413A patent/JP7617640B2/ja active Active
-
2023
- 2023-02-17 US US18/111,143 patent/US20230390241A1/en active Pending
-
2024
- 2024-01-05 US US18/405,593 patent/US12478609B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530671A5 (cg-RX-API-DMAC7.html) | ||
| ES2902360T3 (es) | Inhibidores de PD-1/PD-L1 | |
| JP7783870B2 (ja) | キナーゼ阻害剤の結晶性形態及び塩形態 | |
| CA3101640A1 (en) | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto | |
| JP2016505586A5 (cg-RX-API-DMAC7.html) | ||
| JP2020532529A (ja) | 抗癌剤としての環状ジヌクレオチド | |
| ES3008963T3 (en) | Crystalline salt forms of a kinase inhibitor | |
| US20240065987A1 (en) | Anti-cancer activity of adamantane derivatives | |
| JP2019509316A (ja) | ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体 | |
| US20250368606A1 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| WO2019076269A1 (zh) | 甲羟戊酸通路抑制剂及其药物组合物 | |
| CN107207451A (zh) | 用于治疗人乳头状瘤病毒(hpv)诱导的癌症的化合物 | |
| HK40104785A (en) | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | |
| WO2021132550A1 (ja) | 術後補助療法剤 | |
| EA048718B1 (ru) | Кристаллические солевые формы ингибитора киназы | |
| HK40067664B (zh) | 激酶抑制剂的结晶盐形式 | |
| TW200526201A (en) | Treating bone-related disorders with selective androgen receptor modulators |